The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully ...

This study proposes a cross-species transcriptomic framework to predict vaccine reactogenicity, with implications for preclinical vaccine safety assessment. The findings show that mouse muscle ...

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of ...

The 2026 Forbes Healthcare Summit will convene the world's most influential leaders in healthcare, medicine and science.

Wondering how to stay safe in Mexico? We're here to help — and this article lists the Top 25 most important Mexico safety ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...

Hit the road for Illinois’ coolest winter escapes. Think frozen canyons, snowy trails, ski slopes, eagle watching, and ...

For millions of people who live with racing thoughts and a pounding heart, help might already be sitting in the medicine ...

Novo Nordisk advanced coramitug into the Phase III CLEOPATTRA trial, evaluating 1,280 patients with amyloid transthyretin cardiomyopathy or ATTR-CM. This decision was informed by results from their ...

Q4 2025 Earnings Call February 19, 2026 4:30 PM ESTCompany ParticipantsCaitlin Lowie - Vice President of Corporate Communications ...

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...